Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Amgen K.K.

Home Clinical Trial Sponsors and OrganizationsAmgen K.K.

Amgen K.K.

9-7-1, AKASAKA, Minato-Ku, Tokyo, Japan

Part of Amgen, Inc.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

71

15 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

8

11.3%

Phase 2

6

8.4%

Phase 3

6

8.4%

Trial Status Distribution

Active, not recruiting

14

19.7%

Completed

23

32.4%

Not yet recruiting

1

1.4%

Recruiting

25

35.2%

Suspended

3

4.2%

Terminated

5

7.0%

Clinical Trials

Trials sponsored by this organization (71)

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)

Mar 2025999 participants

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-1)

Mar 20253,501 participants

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

Feb 2025240 participants

Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)

Jan 202510 participants

A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC

Dec 2024200 participants

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer

Dec 2024675 participants

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Active, not recruiting

Nov 2024350 participants

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Oct 2024100 participants

Page 1 of 9

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials71
Approvals
News

Back to Organizations